[go: up one dir, main page]

NO20084008L - HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme - Google Patents

HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme

Info

Publication number
NO20084008L
NO20084008L NO20084008A NO20084008A NO20084008L NO 20084008 L NO20084008 L NO 20084008L NO 20084008 A NO20084008 A NO 20084008A NO 20084008 A NO20084008 A NO 20084008A NO 20084008 L NO20084008 L NO 20084008L
Authority
NO
Norway
Prior art keywords
peptide
amino acid
pharmaceutical composition
hla
restricted
Prior art date
Application number
NO20084008A
Other languages
English (en)
Norwegian (no)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of NO20084008L publication Critical patent/NO20084008L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G01N33/575—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
NO20084008A 2006-02-22 2008-09-19 HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme NO20084008L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006045287 2006-02-22
PCT/JP2007/053176 WO2007097358A1 (ja) 2006-02-22 2007-02-21 Ｈｌａ－ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
NO20084008L true NO20084008L (no) 2008-11-24

Family

ID=38437397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084008A NO20084008L (no) 2006-02-22 2008-09-19 HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme

Country Status (22)

Country Link
US (5) US8759483B2 (es)
EP (3) EP1988163B1 (es)
JP (1) JP5393144B2 (es)
KR (1) KR101391561B1 (es)
CN (3) CN102250211A (es)
AU (1) AU2007218649B2 (es)
BR (1) BRPI0708125A2 (es)
CA (4) CA2886551A1 (es)
CY (1) CY1113117T1 (es)
DK (2) DK2518149T3 (es)
ES (3) ES2387685T3 (es)
IL (4) IL193026A (es)
MX (1) MX2008010842A (es)
MY (1) MY149527A (es)
NO (1) NO20084008L (es)
PH (1) PH12012502372B1 (es)
PL (1) PL1988163T3 (es)
PT (1) PT1988163E (es)
RU (2) RU2435782C2 (es)
SI (1) SI1988163T1 (es)
WO (1) WO2007097358A1 (es)
ZA (1) ZA200806542B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
SI1988163T1 (sl) 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CA2677075C (en) 2007-02-27 2018-07-10 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
CN103619882B (zh) * 2011-04-01 2016-10-19 纪念斯隆-凯特琳癌症中心 对hla-a2呈递的wt1肽特异的t细胞受体样抗体
CA2846479A1 (en) 2011-09-14 2013-03-21 International Institute Of Cancer Immunology, Inc. Method for measuring anti-wt1 antibody
EP2802347B1 (en) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
MX364732B (es) 2012-12-13 2019-05-06 Univ Pennsylvania Vacuna contra el tumor de wilms 1.
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099C (en) 2013-01-15 2025-09-16 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 Peptides and Their Methods of Use
JP2014169275A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 粘膜投与用ワクチン組成物
RU2014102944A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Композиция вакцины для трансдермального или трансмукозального введения
KR20140100422A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 백신 조성물
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
US20140220056A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
CA2841014A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Tape preparation of wt1 peptide cancer vaccine for transdermal administration
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CN114949171A (zh) * 2014-12-11 2022-08-30 株式会社癌免疫研究所 血管生成性疾病的免疫疗法
HK1243960A1 (zh) 2014-12-25 2018-07-27 International Institute Of Cancer Immunology, Inc. T细胞群的改变方法
CA2987247A1 (en) 2015-03-20 2016-09-29 The Trustees Of The University Of Pennsylvania Isg15 and its use as an adjuvant
WO2018088439A1 (ja) 2016-11-09 2018-05-17 国立大学法人大阪大学 Ｔ細胞集団の改変方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6270777B1 (en) * 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
KR100752065B1 (ko) * 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US6797695B1 (en) * 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
AU2001285018A1 (en) * 2000-08-17 2002-02-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
EP1536009B1 (en) 2002-06-12 2010-04-28 International Institute of Cancer Immunology, Inc. Hla-a24-restricted cancer antigen peptide
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
ES2332590T3 (es) 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2004067716A2 (en) * 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US6980709B2 (en) 2003-06-20 2005-12-27 Northrop Grumman Corporation Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
SI1988163T1 (sl) 2006-02-22 2012-09-28 Int Inst Cancer Immunology Inc HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje

Also Published As

Publication number Publication date
RU2435782C2 (ru) 2011-12-10
EP2518149B1 (en) 2015-12-16
PL1988163T3 (pl) 2012-11-30
CN102702319A (zh) 2012-10-03
DK2518149T3 (en) 2016-01-11
IL218172A0 (en) 2012-03-29
AU2007218649A1 (en) 2007-08-30
US20120195918A1 (en) 2012-08-02
CN102702319B (zh) 2015-01-28
MX2008010842A (es) 2008-09-01
JP5393144B2 (ja) 2014-01-22
IL232409A0 (en) 2014-06-30
CN101384716A (zh) 2009-03-11
US20140193442A1 (en) 2014-07-10
CA2886615A1 (en) 2007-08-30
US20140193443A1 (en) 2014-07-10
US8945578B2 (en) 2015-02-03
EP1988163A4 (en) 2010-03-17
CN102250211A (zh) 2011-11-23
PH12012502372A1 (en) 2016-04-04
EP1988163B1 (en) 2012-06-27
CA2886551A1 (en) 2007-08-30
ZA200806542B (en) 2009-07-29
RU2011132212A (ru) 2013-02-10
IL193026A (en) 2015-09-24
RU2008137635A (ru) 2010-03-27
PT1988163E (pt) 2012-08-28
EP2385117A1 (en) 2011-11-09
CA2638122A1 (en) 2007-08-30
IL193026A0 (en) 2009-02-11
US8968745B2 (en) 2015-03-03
ES2387685T3 (es) 2012-09-28
WO2007097358A1 (ja) 2007-08-30
DK1988163T3 (da) 2012-08-20
CY1113117T1 (el) 2016-04-13
ES2587980T3 (es) 2016-10-28
HK1125968A1 (en) 2009-08-21
SI1988163T1 (sl) 2012-09-28
US8759483B2 (en) 2014-06-24
KR20080097203A (ko) 2008-11-04
JPWO2007097358A1 (ja) 2009-07-16
EP1988163A1 (en) 2008-11-05
CA2886552A1 (en) 2007-08-30
EP2518149A1 (en) 2012-10-31
US8933038B2 (en) 2015-01-13
CN101384716B (zh) 2013-03-13
US20100292160A1 (en) 2010-11-18
KR101391561B1 (ko) 2014-05-02
ES2558330T3 (es) 2016-02-03
AU2007218649B2 (en) 2013-01-10
IL232408A0 (en) 2014-06-30
US8778350B2 (en) 2014-07-15
BRPI0708125A2 (pt) 2011-05-17
PH12012502372B1 (en) 2016-04-04
US20140199332A1 (en) 2014-07-17
MY149527A (en) 2013-09-13
EP2385117B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
NO20084008L (no) HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
NO20092774L (no) HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
NO20071369L (no) Antimikrobiske peptider omfattende et arginin- og/eller lysin-inneholdende motiv
BRPI0616824B8 (pt) peptídeo quimérico, seu uso, composição farmacêutica compreendendo o mesmo, e kit
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
MXPA06010347A (es) Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
WO2008113536A8 (en) Neurotrophic peptides
GB2427550A (en) Y2/Y4 selective receptor agonists for therapeutic interventions
MX2023011194A (es) Peptido y composicion que contiene peptido.
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
WO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
EP1842911A4 (en) HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS
EP3771719A8 (en) A peptide binding to tau-protein
DK1915617T3 (da) Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
WO2012073045A3 (en) Variants of trappins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application